LON:APH - Alliance Pharma Stock Price, News, & Analysis Sign in or create an account to add this stock to your watchlist. Get Started GBX 63.60 -0.20 (-0.31 %) (As of 03/22/2019 10:42 AM ET)Previous CloseGBX 63.80Today's RangeGBX 63.34 - GBX 64.6052-Week RangeGBX 59.20 - GBX 102.50Volume571,033 shsAverage Volume488,126 shsMarket Capitalization£329.59 millionP/E Ratio12.72Dividend Yield2.12%BetaN/A ProfileDiscussionAnalyst RatingsChartDividendInsider TradesHeadlinesOptions Chain Share on FacebookShare on TwitterShare on LinkedInShare on RedditShare on StocktwitsPrint this articleShare by Email Alliance Pharma plc operates as a specialty pharmaceutical company in the United Kingdom, rest of Europe, and internationally. The company acquires, markets, and sells pharmaceutical products. It acquires the rights of established products, and owns or licenses the rights to approximately 90 pharmaceutical and consumer healthcare products. The company also provides prescription only medicines, over the counter medications, cosmetics, and nutritional supplements, as well as medical devices. In addition, it offers products in various therapeutic areas, including acquired healthcare, cardiovascular, central nervous system, child health, consumer health, dermatology, endocrinology, gastroenterology, obstetrics and gynecology, oral health, oncology, stoma care, toxicology, travel health, urology, vitamins and minerals, and others. Further, the company provides the Kelo-Cote, a formula silicone treatment used for prevention and forming of scars; MacuShield, an eye care supplement; and Vamousse, a pesticide free consumer healthcare product for prevention and treatment of human heal lice. The company distributes its products through wholesalers, retail pharmacies, hospitals, and network of distributors. Alliance Pharma plc was founded in 1996 and is headquartered in Chippenham, the United Kingdom. Receive APH News and Ratings via Email Sign-up to receive the latest news and ratings for APH and its competitors with MarketBeat's FREE daily newsletter. Industry, Sector and Symbol Stock Exchange LON Industry Drugs - Generic Sub-IndustryN/A SectorMedical Current SymbolLON:APH Previous Symbol CUSIPN/A CIKN/A Webwww.alliancepharma.co.ukallianceenhome Phone+44-1249-466966Debt Debt-to-Equity Ratio41.75 Current Ratio0.57 Quick Ratio0.38Price-To-Earnings Trailing P/E Ratio12.72 Forward P/E Ratio0.15 P/E GrowthN/A Sales & Book Value Annual Sales£108.40 million Price / Sales3.04 Cash FlowGBX 2.98 per share Price / Cash Flow21.33 Book ValueGBX 50.50 per share Price / Book1.26Profitability EPS (Most Recent Fiscal Year)N/A Net IncomeN/A Net MarginsN/A Return on EquityN/A Return on AssetsN/AMiscellaneous Employees200 Outstanding Shares518,230,016Market Cap£329.59 million Next Earnings Date3/26/2019 (Estimated) OptionableOptionable Alliance Pharma (LON:APH) Frequently Asked Questions What is Alliance Pharma's stock symbol? Alliance Pharma trades on the London Stock Exchange (LON) under the ticker symbol "APH." How often does Alliance Pharma pay dividends? What is the dividend yield for Alliance Pharma? Alliance Pharma announced a dividend on Wednesday, September 19th. Stockholders of record on Thursday, December 20th will be given a dividend of GBX 0.49 per share on Thursday, January 10th. This represents a dividend yield of 0.6%. The ex-dividend date of this dividend is Thursday, December 20th. The official announcement can be accessed at this link. View Alliance Pharma's Dividend History. When is Alliance Pharma's next earnings date? Alliance Pharma is scheduled to release their next quarterly earnings announcement on Tuesday, March 26th 2019. View Earnings Estimates for Alliance Pharma. What price target have analysts set for APH? 1 brokers have issued twelve-month price objectives for Alliance Pharma's shares. Their forecasts range from GBX 115 to GBX 115. On average, they anticipate Alliance Pharma's stock price to reach GBX 115 in the next twelve months. This suggests a possible upside of 80.8% from the stock's current price. View Analyst Price Targets for Alliance Pharma. What is the consensus analysts' recommendation for Alliance Pharma? 1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Alliance Pharma in the last year. There are currently 1 buy rating for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Alliance Pharma. Has Alliance Pharma been receiving favorable news coverage? News stories about APH stock have been trending somewhat positive recently, according to InfoTrie Sentiment. The research group identifies positive and negative news coverage by reviewing more than six thousand news and blog sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores nearest to five being the most favorable. Alliance Pharma earned a media sentiment score of 0.8 on InfoTrie's scale. They also assigned media stories about the company a news buzz of 7.0 out of 10, meaning that recent news coverage is likely to have an impact on the company's share price in the near term. Who are some of Alliance Pharma's key competitors? Some companies that are related to Alliance Pharma include Cambrex (CBM), Brookdale Senior Living (BKD), Varex Imaging (VREX), Alector (ALEC), Phibro Animal Health (PAHC), TherapeuticsMD (TXMD), Tabula Rasa HealthCare (TRHC), Iovance Biotherapeutics (IOVA), Natera (NTRA), Clinuvel Pharmaceuticals (CUV), National HealthCare (NHC), CannTrust (TRST), Clinigen Group (CLIN), Concordia International (CXR) and Sienna Senior Living (SIA). What other stocks do shareholders of Alliance Pharma own? Based on aggregate information from My MarketBeat watchlists, some companies that other Alliance Pharma investors own include RPC Group (RPC), BlackBerry (BB), Editas Medicine (EDIT), 1-800-Flowers.Com (FLWS), Air Canada (AC), Ally Financial (ALLY), Direct Line Insurance Group (DLG), Berry Global Group (BERY), Telford Homes (TEF) and Centrica (CNA). Who are Alliance Pharma's key executives? Alliance Pharma's management team includes the folowing people: Mr. Peter Jonathan Butterfield, CEO & Exec. Director (Age 43)Mr. John Dawson, Founder & Non-Exec. Director (Age 70)Mr. Andrew Timothy Franklin, CFO & Exec. Director (Age 53)Mr. Stephen Kidner, Chief Scientific & Operations OfficerMr. Daniel Thomas, Chief Corp. Devel. Officer How do I buy shares of Alliance Pharma? Shares of APH and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock. What is Alliance Pharma's stock price today? One share of APH stock can currently be purchased for approximately GBX 63.60. How big of a company is Alliance Pharma? Alliance Pharma has a market capitalization of £329.59 million and generates £108.40 million in revenue each year. Alliance Pharma employs 200 workers across the globe. What is Alliance Pharma's official website? The official website for Alliance Pharma is http://www.alliancepharma.co.uk/alliance/en/home. How can I contact Alliance Pharma? Alliance Pharma's mailing address is Avonbridge House, Bath Road, CHIPPENHAM, SN15 2BB, United Kingdom. The company can be reached via phone at +44-1249-466966. MarketBeat Community Rating for Alliance Pharma (LON APH)Community Ranking: 2.1 out of 5 ( )Outperform Votes: 171 (Vote Outperform)Underperform Votes: 230 (Vote Underperform)Total Votes: 401MarketBeat's community ratings are surveys of what our community members think about Alliance Pharma and other stocks. Vote "Outperform" if you believe APH will outperform the S&P 500 over the long term. Vote "Underperform" if you believe APH will underperform the S&P 500 over the long term. You may vote once every thirty days. This page was last updated on 3/22/2019 by MarketBeat.com StaffFeatured Article: How is a Moving Average Calculated?